We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News Medica 2024 AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Stratagene and Rosetta Inpharmatics Announce Alliance

By HospiMedica staff writers
Posted on 20 Sep 2006
Stratagene Corp. (La Jolla, CA, USA) and Rosetta Inpharmatics, LLC (Seattle, WA, USA), a wholly-owned subsidiary of Merck & Co., Inc., have entered into a joint development-and-license agreement. The companies will develop an RNA purification system for use in molecular diagnostics and research applications.

Under the terms of the agreement, Stratagene and Rosetta will jointly develop a proprietary instrument and a single-use consumable that will be manufactured and commercialized by Stratagene. These products will be sold to Stratagene's current customer base and companies engaged in pharmacogenomics. Financial terms of the agreement were not disclosed.

The companies plan to create an automated solution for the isolation of nucleic acids from a variety of clinical samples. Nucleic acid purification allows scientists to separate RNA contained in biologic samples. Clinicians and researchers can use the purified RNA to perform gene expression analysis and other functions within molecular diagnostics.

"This agreement with Rosetta Inpharmatics is a significant opportunity for Stratagene and marks another milestone in our molecular diagnostics strategy,” said Joseph A. Sorge, M.D., president and CEO of Stratagene. "We believe we have a unique opportunity to create and introduce a differentiated product that will automate the RNA purification process and provide consistent, reproducible results. These two characteristics are critical capabilities in gene expression analysis.”

Stratagene is a developer, manufacturer, and marketer of specialized life science research and diagnostic products. The company's diagnostic unit develops and manufactures products for urinalysis as well as automated instruments and reagent systems that use blood samples to test for more than 1,000 different allergies and autoimmune disorders. In addition, by combining its expertise in diagnostics and molecular biology, the company is pursuing opportunities to expand its product portfolio to include molecular diagnostic kits and instrumentation.



Related Links:
Stratagene
Rosetta Inpharmatics

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
New
Diagnostic Ultrasound System
MS1700C
New
Transducer Covers
Surgi Intraoperative Covers

Latest Business News

Boston Scientific Acquires Medical Device Company Intera Oncology

MEDICA 2024 to Highlight Hot Topics of MedTech Industry

Start-Ups To Once Again Play Starring Role at MEDICA 2024